Administration of Amphotericin B in Lipid Emulsion

OʼNeil, Michael G.; Lapointe, Marc

doi:10.1097/00003246-199705000-00030

Cited by 4 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 For the last 70 years, the first line of defense has been pentavalent antimonials, sodium stibogluconate (SAG or Pentosam) and meglucamine antimoniate (Glucantime); 2 however, increased drug resistance has brought amphotericin B (AmpB) to the forefront of treatment options as the therapeutic success rate of AmpB is high with no report of either relapse or resistance to AmpB in otherwise immunocompetent patients. 3,4 AmpB, a macrolide heptaene antibiotic, is a classical antifungal drug 5 and possesses various immunomodulatory effects on neutrophils, macrophages, NK cells, T cells and B cells. 6e12 This novel drug with antimicrobial and tumoricidal activities, stimulates the transcription and production of proinflammatory cytokines like TNF-a, IL-1b, MCP-1, MIP-1b, nitric oxide, prostaglandins and intercellular adhesion molecule-1 from murine and human immune cells.…”

Section: Introductionmentioning

confidence: 99%

Amphotericin B regulates the host immune response in visceral leishmaniasis: Reciprocal regulation of protein kinase C isoforms

Mukherjee

Gupta

Bhattacharjee

et al. 2010

Journal of Infection

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Amphotericin B regulates the host immune response in visceral leishmaniasis: Reciprocal regulation of protein kinase C isoforms

Mukherjee

Gupta

Bhattacharjee

et al. 2010

Journal of Infection

View full text Add to dashboard Cite

Amphotericin B

Lemke

Kiderlen

Kayser

2005

Appl Microbiol Biotechnol

286

245

View full text Add to dashboard Cite

Invasive fungal infections are a major cause of morbidity and mortality in immunodeficient individuals (such as AIDS patients) and in transplant recipients or tumor patients undergoing immunosuppressive chemotherapy. Amphotericin B is one of the oldest, yet most efficient antimycotic agents. However, its usefulness is limited due to dose-dependent side-effects, notably nephrotoxicity. In order to improve its safety margin, new pharmaceutical formulations of amphotericin B have been designed especially to reduce its detrimental effects on the kidneys. Since the 1980s, a wide variety of new amphotericin B formulations have been brought forward for clinical testing, many of which were approved and reached market value in the 1990s. This review describes and discusses the molecular genetics, pharmacological, toxicological, and clinical aspects of amphotericin B itself and many of its innovative formulations.

show abstract

Formulation and biopharmaceutical issues in the development of drug delivery systems for antiparasitic drugs

Kayser

Olbrich²,

Croft

et al. 2003

Parasitology Research

View full text Add to dashboard Cite

The development of really new antiparasitic drugs to market level is a very rare event. A large number of lead structures have already been screened and discarded, the market is large but poor, and the administrative barriers are increasingly high and costly. Novel antiparasitics must not only be better, they must also be substantially safer than the existing repertoire. There are two major aspects to drug development. One is the strategy of pathogen-specific biochemical intervention, the other the strategy of optimal formulation and application. This review focuses on the latter. In finding and adapting innovative and "intelligent", i.e. parasite- and disease-specific formulations and delivery systems, established but deficient drugs might be optimised, enhancing their efficiency and reducing negative side effects at relatively low cost. Further, many promising new ideas are severely hampered by the low water solubility of the antiparasitic drug. Here as well, some of the innovative drug formulation and delivery systems discussed below might offer highly efficient, while technologically simple, solutions.

show abstract

Administration of Amphotericin B in Lipid Emulsion

Cited by 4 publications

References 7 publications

Amphotericin B regulates the host immune response in visceral leishmaniasis: Reciprocal regulation of protein kinase C isoforms

Amphotericin B regulates the host immune response in visceral leishmaniasis: Reciprocal regulation of protein kinase C isoforms

Amphotericin B

Formulation and biopharmaceutical issues in the development of drug delivery systems for antiparasitic drugs

Contact Info

Product

Resources

About